Cell Genesys GVAX Prostate Cancer Vaccine To Start Phase III Second-Quarter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cell Genesys’ GVAX prostate cancer vaccine is scheduled to enter Phase III at the end of the second quarter under FDA’s special protocol assessment program.
You may also be interested in...
Cell Genesys GVAX second pivotal begins
Cell Genesys is initiating a second Phase III trial of its therapeutic prostate cancer vaccine GVAX, the firm says July 5. The VITAL-2 study in patients with metastatic hormone-refractory prostate cancer "is the other key component of the company's product registration strategy." The other pivotal trial, VITAL-1 , is still enrolling. VITAL-2 will compare GVAX plus Sanofi-Aventis' Taxotere to Taxotere plus prednisone; VITAL-1 is looking at GVAX vs. Taxotere/prednisone. Both trials are designed to show superiority with respect to survival. VITAL-1 is being conducted under a special protocol assessment with FDA (1Pharmaceutical Approvals Monthly May 2004, p. 5)...
Antigenics Oncophage Retrospective Testing For Potency Is Approval Issue
Approval of Antigenics’ Phase III cancer vaccine Oncophage rests on whether FDA will accept retrospective testing of vaccine used in pivotal trials to support product characterization, the company said.
Antigenics Oncophage Retrospective Testing For Potency Is Approval Issue
Approval of Antigenics’ Phase III cancer vaccine Oncophage rests on whether FDA will accept retrospective testing of vaccine used in pivotal trials to support product characterization, the company said.